Briefing
The prognostic value of tumor-informed minimal residual disease detection using circulating tumor DNA in first-line treatment of ovarian cancer
In 31 patients with stage II–IV ovarian cancer in complete remission after first-line surgery and platinum chemotherapy (no first-line PARP-inhibitor maintenance), landmark post-treatment MRD positivity was associated with shorter median PFS (5.8 vs 24.7 months, HR 6.678, P=0.01).
- Design: Evidence level 3
- Assay: Not named in the abstract